EDGe Surgical Receives CE Mark Certification for EDG® Ortho 65mm Electronic Depth Gauge

EDGe Surgical, Inc., develops and manufactures smart orthopedic and spine surgical instruments. Today they announced they have received a CE Certificate of Conformity from its notified body permitting CE mark of the company’s EDG® Ortho 65mm single-use electronic depth gauge in the European Union market.

“This is a great achievement for EDGe Surgical on several levels,” said Christopher Wilson, CEO, EDGe Surgical, Inc. “The approval enables us to gain access to markets that accept CE-marked medical devices, and it also sets the stage for strategic partnerships with larger manufacturers who are not ready to transition to the new EU Medical Device Regulation (MDR) that goes into effect later this month.”

Under the MDR, traditional metal depth gauges will be reclassified to a higher, riskier classification and must be certified by a “notified body” instead of self-certification by the manufacturer. Notified bodies are organizations designated by an EU country to assess the conformity of certain products before being placed on the market.

“Preparing for the requirements under the new MDR is placing significant resource strain on large orthopedic manufacturers, and some have made the tough decision to discontinue certain products due to lack of readiness,” Wilson continued. “Our EDG Ortho electronic depth gauge is a readily available option for manufacturers that are having difficulty transitioning their legacy metal depth gauges to the more stringent requirements.”

The EDG Ortho is a sterile, single-use device used to more accurately and safely measure which length screw should be implanted into a patient during orthopedic fracture surgeries.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Led by researchers at NYU Grossman School of Medicine, the study results add to evidence that neighboring brain regions, the inferior frontal gyrus and the motor cortex, play an important role in such planning before words are said aloud. Both are part of the folded top layers of the brain, or cerebral cortex, which has long been known to control the muscle (motor) movements in the throat and mouth needed to produce speech. Less clear until now was how closely these regions determine the mix of sounds and words people want to say aloud, the authors report.
PolarisAR describes STELLAR Knee as a mixed-reality surgical navigation platform that guides TKA procedures by displaying measured and computed data overlaid directly in a 3D environment. The mixed-reality system acts as a spatial computer, creating continuous data exchange between the surgeon and the software to help enhance surgical decision-making while simplifying operating room workflow.
This February, the first enrolled patient underwent open surgical aortic arch reconstruction at the University of Pennsylvania, Presbyterian Medical Center, Philadelphia, PA.  During the surgery, the Duett Vascular Graft System was successfully deployed to connect the native left common carotid artery to the surgical graft.
"Our ultra low insertion loss Athermal AWG Multiplexers along with temperature-hardened low-drift AAWG specifically designed for the industrial temperature applications will be marketed aggressively through partnership companies in the East Asia and EU regions after its success in the North America," says Dr. Donald Yu, CMO of POINTek, who runs global marketing operations from Los Angeles, California.
AUX-001 is an innovative, once-daily, extended-release formulation of Nicorandil. For decades, immediate-release, twice daily Nicorandil has been a cornerstone treatment for chronic angina symptoms outside the US, distinguished by its dual mechanism of action that targets both the micro- and macrovascular coronary artery flow bed, and providing sustained angina symptom relief without the common issue of tachyphylaxis seen with other anti-anginal vasodilators like long-acting nitrates. AUX-001 offers efficacy comparable to conventional anti-anginal medications such as beta-blockers, calcium channel blockers, and long-acting nitrates while also potentially enhancing control of the underlying coronary disease and reducing angina related hospitalizations.

By using this website you agree to accept Medical Device News Magazine Privacy Policy